AUPQ014799A0 - Amplification of folate-mediated targeting to tumor cells using polymers - Google Patents

Amplification of folate-mediated targeting to tumor cells using polymers

Info

Publication number
AUPQ014799A0
AUPQ014799A0 AUPQ0147A AUPQ014799A AUPQ014799A0 AU PQ014799 A0 AUPQ014799 A0 AU PQ014799A0 AU PQ0147 A AUPQ0147 A AU PQ0147A AU PQ014799 A AUPQ014799 A AU PQ014799A AU PQ014799 A0 AUPQ014799 A0 AU PQ014799A0
Authority
AU
Australia
Prior art keywords
folate
amplification
polymers
tumor cells
mediated targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AUPQ0147A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Access Pharmaceuticals Australia Pty Ltd
Original Assignee
Biotech Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotech Australia Pty Ltd filed Critical Biotech Australia Pty Ltd
Priority to AUPQ0147A priority Critical patent/AUPQ014799A0/en
Publication of AUPQ014799A0 publication Critical patent/AUPQ014799A0/en
Priority to AU40943/00A priority patent/AU4094300A/en
Priority to PCT/AU2000/000406 priority patent/WO2000066091A1/en
Priority to CA002372841A priority patent/CA2372841A1/en
Priority to JP2000614977A priority patent/JP2002543111A/en
Priority to EP00920286A priority patent/EP1206252A4/en
Assigned to ACCESS PHARMACEUTICALS AUSTRALIA PTY LIMITED reassignment ACCESS PHARMACEUTICALS AUSTRALIA PTY LIMITED Assignment by Applicant under S 113 Assignors: BIOTECH AUSTRALIA PTY LIMITED
Assigned to ACCESS PHARMACEUTICALS AUSTRALIA PTY LIMITED reassignment ACCESS PHARMACEUTICALS AUSTRALIA PTY LIMITED Alteration of Name(s) of Applicant(s) under S113 Assignors: BIOTECH AUSTRALIA PTY LIMITED
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B11/00—Preparation of cellulose ethers
    • C08B11/20—Post-etherification treatments of chemical or physical type, e.g. mixed etherification in two steps, including purification
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0069—Chondroitin-4-sulfate, i.e. chondroitin sulfate A; Dermatan sulfate, i.e. chondroitin sulfate B or beta-heparin; Chondroitin-6-sulfate, i.e. chondroitin sulfate C; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/52—Amides or imides
    • C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
    • C08F220/58—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide containing oxygen in addition to the carbonamido oxygen, e.g. N-methylolacrylamide, N-(meth)acryloylmorpholine
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F251/00—Macromolecular compounds obtained by polymerising monomers on to polysaccharides or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F251/00—Macromolecular compounds obtained by polymerising monomers on to polysaccharides or derivatives thereof
    • C08F251/02—Macromolecular compounds obtained by polymerising monomers on to polysaccharides or derivatives thereof on to cellulose or derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AUPQ0147A 1999-05-04 1999-05-04 Amplification of folate-mediated targeting to tumor cells using polymers Abandoned AUPQ014799A0 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AUPQ0147A AUPQ014799A0 (en) 1999-05-04 1999-05-04 Amplification of folate-mediated targeting to tumor cells using polymers
AU40943/00A AU4094300A (en) 1999-05-04 2000-05-04 Amplification of folate-mediated targeting to tumor cells using polymers
PCT/AU2000/000406 WO2000066091A1 (en) 1999-05-04 2000-05-04 Amplification of folate-mediated targeting to tumor cells using polymers
CA002372841A CA2372841A1 (en) 1999-05-04 2000-05-04 Amplification of folate-mediated targeting to tumor cells using polymers
JP2000614977A JP2002543111A (en) 1999-05-04 2000-05-04 Amplification of folate-mediated targeting to tumor cells using polymers
EP00920286A EP1206252A4 (en) 1999-05-04 2000-05-04 Amplification of folate-mediated targeting to tumor cells using polymers

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPQ0147A AUPQ014799A0 (en) 1999-05-04 1999-05-04 Amplification of folate-mediated targeting to tumor cells using polymers

Publications (1)

Publication Number Publication Date
AUPQ014799A0 true AUPQ014799A0 (en) 1999-05-27

Family

ID=3814354

Family Applications (2)

Application Number Title Priority Date Filing Date
AUPQ0147A Abandoned AUPQ014799A0 (en) 1999-05-04 1999-05-04 Amplification of folate-mediated targeting to tumor cells using polymers
AU40943/00A Abandoned AU4094300A (en) 1999-05-04 2000-05-04 Amplification of folate-mediated targeting to tumor cells using polymers

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU40943/00A Abandoned AU4094300A (en) 1999-05-04 2000-05-04 Amplification of folate-mediated targeting to tumor cells using polymers

Country Status (5)

Country Link
EP (1) EP1206252A4 (en)
JP (1) JP2002543111A (en)
AU (2) AUPQ014799A0 (en)
CA (1) CA2372841A1 (en)
WO (1) WO2000066091A1 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60231868D1 (en) 2001-04-24 2009-05-20 Purdue Research Foundation FOLAT MIMETICS AND THEIR FOLAT RECEPTOR BINDING CONJUGATES
ATE451935T1 (en) * 2001-09-28 2010-01-15 Purdue Research Foundation TREATMENT METHODS USING LIGAND-IMMUNOGEN CONJUGATES
ATE426414T1 (en) * 2002-05-15 2009-04-15 Endocyte Inc VITAMIN-MITOMYCIN CONJUGATES
AU2002953073A0 (en) * 2002-11-21 2003-01-16 Access Pharmaceuticals Australia Pty Limited Amplification of biotin-mediated targeting
AR042942A1 (en) * 2003-01-27 2005-07-06 Endocyte Inc CONJUGATES OF DRUG ADMINISTRATION OF VITAMIN RECEPTORS UNION
US8288557B2 (en) 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
US8044200B2 (en) 2005-03-16 2011-10-25 Endocyte, Inc. Synthesis and purification of pteroic acid and conjugates thereof
US8465724B2 (en) * 2005-08-19 2013-06-18 Endocyte, Inc. Multi-drug ligand conjugates
JP5350792B2 (en) 2005-08-24 2013-11-27 イムノゲン インコーポレーティッド Method for preparing maytansinoid antibody complex
WO2007080114A2 (en) * 2006-01-11 2007-07-19 Biotech Igg Ab Macromolecule conjugate
PE20080316A1 (en) 2006-05-25 2008-04-10 Bristol Myers Squibb Co AZIRIDINYL-EPOTILONE COMPOUNDS
PE20080102A1 (en) * 2006-05-25 2008-02-11 Bristol Myers Squibb Co AZIRIDINYL-EPOTILONE CONJUGATES AND PHARMACEUTICAL COMPOSITIONS INCLUDING THE SAME
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
JP5829793B2 (en) 2007-03-14 2015-12-09 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． Drug delivery conjugates of tubricin bound by a binding ligand
DK2155254T3 (en) * 2007-05-09 2013-03-04 Nitto Denko Corp Polymer conjugated with platinum drugs
JP2010528115A (en) 2007-05-25 2010-08-19 ブリストル−マイヤーズ スクイブ カンパニー Epothilone compound and method for producing analog
EP2176293B1 (en) * 2007-06-25 2019-04-03 Endocyte, Inc. Conjugates containing hydrophilic spacer linkers
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CN104873982A (en) 2007-08-17 2015-09-02 普渡研究基金会 PSMA binding ligand-linker conjugates and methods of use thereof
AU2008316835B2 (en) 2007-10-25 2015-07-16 Endocyte, Inc. Tubulysins and processes for preparing
WO2009133545A2 (en) * 2008-04-30 2009-11-05 Ben Gurion University Of The Negev Research And Development Authority Vascular delivery systems
CA2737496A1 (en) 2008-09-17 2010-03-25 Endocyte, Inc. Folate receptor binding conjugates of antifolates
WO2010042638A2 (en) 2008-10-07 2010-04-15 Young Bok Lee Hpma - docetaxel or gemcitabine conjugates and uses therefore
EP2210616A1 (en) * 2009-01-21 2010-07-28 Centre National de la Recherche Scientifique Multifunctional stealth nanoparticles for biomedical use
LT2437790T (en) 2009-06-03 2019-06-10 Immunogen, Inc. Conjugation methods
AU2010306917B2 (en) 2009-10-13 2014-11-27 Rexahn Pharmaceuticals, Inc. Polymeric systems for the delivery of anticancer agents
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
DK2691155T3 (en) 2011-03-29 2019-03-04 Immunogen Inc PREPARATION OF MAYTANSINOID ANTIBODY CONJUGATES BY A STEP PROCEDURE
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
IN2015DN03202A (en) 2012-10-04 2015-10-02 Immunogen Inc
JP2015536323A (en) 2012-10-16 2015-12-21 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． Drug delivery conjugates comprising unnatural amino acids and methods of use
KR102499944B1 (en) 2012-11-15 2023-02-14 엔도사이트, 인코포레이티드 Conjugates for treating diseases caused by psma expressing cells
MY194484A (en) 2013-10-18 2022-11-30 Deutsches Krebsforsch Labeled Inhibitors of Prostate Specific Membrane Antigen (PSMA), Their use as Imaging Agents and Pharmaceutical Agents for the Treatment of Prostate Cancer
AU2014348601A1 (en) 2013-11-14 2016-05-26 Endocyte, Inc. Compounds for positron emission tomography
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
WO2017219029A2 (en) 2016-06-17 2017-12-21 Magenta Therapeutics, Inc. Compositions and methods for the depletion of cd117+cells
CN106619571B (en) * 2017-01-03 2020-04-07 西南交通大学 Polymer nano-carrier for improving endocytosis and cell nucleus targeting and preparation method thereof
TWI825007B (en) 2017-01-20 2023-12-11 德商海德堡醫藥研究有限責任公司 Compositions and methods for the depletion of cd137+ cells
JP7249591B2 (en) * 2018-03-29 2023-03-31 日油株式会社 Degradable polyethylene glycol conjugate
MX2020010813A (en) 2018-04-17 2021-01-08 Endocyte Inc Methods of treating cancer.
US11484601B2 (en) 2018-05-04 2022-11-01 Twinpigbiolab Inc. Targeting M2-like tumor-associated macrophages by using melittin-based proapoptotic peptide
CN112608398B (en) * 2020-11-30 2022-04-22 西安交通大学 A reduced/pH-sensitive polysaccharide-based nanoprodrug co-loaded with doxorubicin and platinum drugs and its preparation method and application

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2044663A1 (en) * 1990-07-12 1992-01-13 Makoto Tanaka Water-dispersible polyene antifungal complexes
US5449720A (en) * 1993-05-24 1995-09-12 Biotech Australia Pty Limited Amplification of the VB12 uptake system using polymers
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
GB9600272D0 (en) * 1996-01-06 1996-03-06 Univ Nottingham Polymers
TW520297B (en) * 1996-10-11 2003-02-11 Sequus Pharm Inc Fusogenic liposome composition and method
JP2002532407A (en) * 1998-12-18 2002-10-02 アルザ・コーポレーション Method of administering compound to multidrug resistant cells

Also Published As

Publication number Publication date
JP2002543111A (en) 2002-12-17
CA2372841A1 (en) 2000-11-09
EP1206252A4 (en) 2005-02-16
WO2000066091A1 (en) 2000-11-09
AU4094300A (en) 2000-11-17
EP1206252A1 (en) 2002-05-22

Similar Documents

Publication Publication Date Title
AUPQ014799A0 (en) Amplification of folate-mediated targeting to tumor cells using polymers
AUPQ014699A0 (en) Amplification of folate-mediated targeting to tumor cells using nanoparticles
AU2001292728A1 (en) Compositions and methods for identifying and targeting stomach and esophageal cancer cells
AU2001280767A1 (en) Peptide-mediated delivery of molecules into cells
AU5731400A (en) Methods of preparing electrochemical cells
AU1796601A (en) Methods of preparing electrochemical cells
AU5481000A (en) Combination cancer therapy comprising adenosine and deaminase enzyme inhibitor
AU7994200A (en) Compositions and methods for therapy and diagnosis of prostate cancer
AU2001288686A1 (en) Improved cardiac function through administration of es cells
AU2001231204A1 (en) Genetically engineered tumor cell vaccines
AU1922301A (en) Differential gene expression in cancer
AU3928300A (en) Genes associated with diseases of the kidney
AU2002217760A1 (en) Targeting drug/gene carriers to irradiated tissue
EP1635764A4 (en) Conjugate for the specific targeting of anticancer agents to cancer cells and production thereof
AU6208100A (en) Cancer treatment using angiopoietins targeted to aminophospholipids
AU2002235168A1 (en) Targeting pluripotent stem cells to tissues
WO2002030941A3 (en) Topoisomerase inhibitors
AU2452197A (en) Genes amplified in cancer cells
AU2002245031A1 (en) Compositions and methods relating to prostate specific genes and proteins
AU4009899A (en) Molecules targeting cd40 and tumor cells
AU2135001A (en) Targeting of endosomal growth factor processing as anti-cancer therapy
AU1916601A (en) Oncolytic combinations for the treatment of cancer
AU2001272967A1 (en) Imaging and targeting tumors using sickle cells
GB0011060D0 (en) Improvements relating to gene directed enzyme prodrug therapy
AU1916501A (en) Oncolytic combinations for the treatment of cancer

Legal Events

Date Code Title Description
NAA1 Application designating australia and claiming priority from australian document

Ref document number: 4094300

Country of ref document: AU

PC1 Assignment before grant (sect. 113)

Owner name: ACCESS PHARMACEUTICALS AUSTRALIA PTY. LTD.

Free format text: THE FORMER OWNER WAS: BIOTECH AUSTRALIA PTY. LIMITED